Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form
Reexamination Certificate
2001-03-23
2003-10-07
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
C424S451000, C424S464000, C424S449000, C424S489000
Reexamination Certificate
active
06630149
ABSTRACT:
This application a 371 of PCT/EP99/04614 filed Jul. 2, 1999.
The invention relates to a dosage form for medicinal active ingredients in blister form, which makes it possible to administer simultaneously a transdermal therapeutic system (TTS) and at least one single-dose active ingredient.
It is customary in hormone replacement therapy to combine administration of the basic hormone with administration of another hormone in order to avoid side effects. This applies, for example, to oestradiol administration, which takes place with administration of a gestagen. Since long-term, continuous administration of the basic hormone is desired, a suitable administration form has proved to be the transdermal therapeutic system (TTS), with which the active ingredient is delivered to the skin in controlled manner via a defined contact area of an active ingredient reservoir. The system preferably comprises a pressure-sensitive adhesive. If discontinuous concomitant medication with another hormone is desired, this usually takes place in tablet form. The tablets are normally stored separately and can be manipulated in accordance with the administration schedule only with difficulty. This type of dosage forms is thus extremely unfavourable for patient compliance.
It was therefore an object of the invention, for compliance reasons, to create a suitable packaging procedure for simultaneous administration of medicinal active ingredients via the transdermal and non-transdermal route. This was intended to ensure that the patient is aided, by an appropriate design of packaging, in implementing where possible intake of single doses at defined times.
The achievement of the object has now been found in a blister form which, besides the TTS, contains at least one single-dose active ingredient form. The TTS is packed individually in a blister but may also be fixed to the dosage form in another way, such as, for example, by means of the pressure-sensitive adhesive contact area. Accommodation in a blister is also the method of choice for the single-dose active ingredient form, which is preferably a tablet, it also being possible, of course, to conceive other attachment mechanisms.
Joining together several blister forms has proved advantageous for longer-term administration. This means for the patient that his administration regimen is fixed accurately and unambiguously for weeks. The series of blister forms may perfectly well include those which have no single-dose active ingredient form, if required for therapeutic reasons.
The single-dose active ingredient form is usually designed for non-transdermal administration. Otherwise, care must be taken that bolus-like release is ensured. Besides or in place of systemic active ingredients it is possible for the single-dose active ingredient form also to contain preparations for topical pretreatment and/or after-treatment of the TTS administration area. These preparations may, for example, improve the skin permeability of the active ingredient from the TTS or prevent or even reverse harmful skin changes after administration of the TTS. Last but not least, the single-dose active ingredient form may also contain one or more TTS active ingredients in order to cover the TTS lag time or generate an additional plasma peak required by the circadian rhythm.
REFERENCES:
patent: 4736849 (1988-04-01), Leonard et al.
patent: 5108995 (1992-04-01), Casper
patent: 5686112 (1997-11-01), Liedtke
patent: 5855905 (1999-01-01), Oettel et al.
patent: 297 19 070 (1997-10-01), None
patent: 0307352 (1988-07-01), None
patent: 0307352 (1989-03-01), None
patent: WO 9109731 (1991-07-01), None
patent: WO 9901132 (1999-01-01), None
Asmussen Bodo
Franke Hanshermann
Schaefer Wolfgang
Bennett Rachel M.
Jordan and Hamburg LLP
LTS Lohmann Therapie Systeme AG
Page Thurman K.
LandOfFree
Blister containing a transdermal therapeutic system and a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Blister containing a transdermal therapeutic system and a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Blister containing a transdermal therapeutic system and a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3131421